CymaBay Therapeutics to Present New Data Highlighting Seladelpar’s Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

By /

CymaBay Therapeutics, Inc. announced it will make three presentations at the European Association for the Study of the Liver ‘s The International Liver Congress™ 2023.

Scroll to Top